1,033 results match your criteria: "" Centre Henri Becquerel[Affiliation]"
ESMO Open
June 2022
INSERM Unit 981 - Molecular Predictors and New Targets in Oncology, Gustave Roussy, Villejuif, France. Electronic address:
Background: Clinical trials allow development of innovative treatments and ameliorate the quality of clinical care in oncology. Data show that only a minority of patients are enrolled in clinical trials. We assessed enrolment in clinical trials and its correlates among women with early breast cancer.
View Article and Find Full Text PDFHaematologica
January 2023
Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne.
Front Oncol
May 2022
Départment of Radiation Oncology, Centre Henri Becquerel, Rouen, France.
Introduction: Stereotactic body radiotherapy (SBRT) is a treatment option for spine metastases. The International Spine Radiosurgery Consortium (ISRC) has published consensus guidelines for target delineation in spine SBRT. A new software called Elements™ Spine SRS by Brainlab that includes the module Elements SmartBrush Spine (v3.
View Article and Find Full Text PDFHaematologica
December 2022
Department of Hematology, Dijon-Bourgogne University Hospital, Dijon; INSERM unit 1231, University of Burgundy Franche-Comté, France.
Entropy (Basel)
May 2022
LITIS, Quantif, University of Rouen, 76000 Rouen, France.
Alexandre Huat, Sébastien Thureau, David Pasquier, Isabelle Gardin, Romain Modzelewski, David Gibon, Juliette Thariat and Vincent Grégoire were not included as authors in the original publication [...
View Article and Find Full Text PDFHemasphere
June 2022
Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Cancer
August 2022
Haematology Department, AP-HP, Saint Antoine Hospital, Paris, France.
Background: The presence of TP53 mutations is associated with an unfavorable outcome in patients allografted for acute myeloid leukemia (AML), leading some to question the benefit of an allogeneic stem cell transplantation (allo-SCT) for this patient group, although this has not been studied in a large cohort.
Methods: A total of 780 patients with AML in first complete remission, with either intermediate- or adverse-risk cytogenetics, whose TP53 mutation status was reported, were included in this study from the European Society for Blood and Marrow Transplantation.
Results: Two-year overall survival (OS) was impaired in patients (n = 179) with evidence of a TP53 mutation at diagnosis (35.
Blood
May 2022
Service d'hématologie, Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Toulouse, France.
Int J Cancer
October 2022
Department of Radiation Oncology, Institut Curie, Paris, Paris, France.
Skin damage is the most common and most important toxicity during and after radiation therapy (RT). Its assessment and understanding of the factors influencing its occurrence, is a major issue in the management of patients irradiated for an early breast cancer. CANTO is a prospective clinical cohort study of 10 150 patients with stage I-III BC treated from 2012 to 2017 in 26 cancer centres.
View Article and Find Full Text PDFHematol Oncol
October 2022
Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Psychooncology
August 2022
Department of Clinical Research, UNICANCER, Centre François Baclesse, Caen, France.
Background: Art therapy (AT) as supportive care may help patients cope with cancer treatments. This non-blinded randomized trial assessed the impact of creative AT on severe fatigue and quality of life (QoL) in localized breast cancer patients undergoing irradiation.
Material And Methods: 320 patients were randomized to an AT group (ATG; 8 weekly sessions starting during irradiation) or to a standard group (SG).
Eur J Nucl Med Mol Imaging
July 2022
Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.
Ann Diagn Pathol
August 2022
Department of Clinical Haematology, Centre Henri Becquerel, Rouen 76038, France. Electronic address:
Context: Bone marrow biopsy (BMB) is a common procedure in haematology used for the diagnosis and evaluation of response treatment. Because the procedure is difficult for haematologists to perform, patients often experience pain and stress. On Control, a system device, was introduced in the 2000s and uses a drill-powered needle to perform BMB.
View Article and Find Full Text PDFEntropy (Basel)
March 2022
LITIS, Quantif, University of Rouen, 76000 Rouen, France.
In this paper, we propose to quantitatively compare loss functions based on parameterized Tsallis-Havrda-Charvat entropy and classical Shannon entropy for the training of a deep network in the case of small datasets which are usually encountered in medical applications. Shannon cross-entropy is widely used as a loss function for most neural networks applied to the segmentation, classification and detection of images. Shannon entropy is a particular case of Tsallis-Havrda-Charvat entropy.
View Article and Find Full Text PDFCancers (Basel)
April 2022
INSERM U1245, Normandie University, UNIROUEN, UNICAEN, 14032 Caen, France.
PLoS One
April 2022
Tumor Biology and Tumor Bank Department, University Hospital of Bordeaux, Bordeaux, France.
Transfusion
May 2022
Service d'hématologie, CHU Grenoble Alpes, Université Grenoble Alpes, Institute for Advanced Biosciences, Grenoble, France.
Br J Haematol
July 2022
Department of Hematology, University Hospital of Rennes, Rennes, France.
Br J Haematol
August 2022
Hématologie Sénior Hôpital Saint Louis, Assistance publique hôpitaux de paris, and Université de Paris Cité, Paris, France.
In order to improve the outcome observed with azacitidine (AZA) in higher-risk Myelodysplastic syndrome (MDS), its combination with other drugs in MDS must be evaluated. So far, no combination has not been shown to be more effective than AZA alone. AZA-PLUS was a phase II trial that, in a "pick a winner" approach, randomly assigned patients with higher-risk MDS, CMML and low blast count AML to: AZA; AZA plus lenalidomide; AZA plus Valproic Acid or AZA plus Idarubicin.
View Article and Find Full Text PDFLeukemia
June 2022
EA 7453 CHELTER, Université Clermont Auvergne, Clermont-Ferrand, France.
Karyotype complexity has major prognostic value in many malignancies. There is no consensus on the definition of a complex karyotype, and the prognostic impact of karyotype complexity differs from one disease to another. Due to the importance of the complex karyotype in the prognosis and treatment of several hematological diseases, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) has developed an up-to-date, practical document for helping cytogeneticists to assess complex karyotypes in these hematological disorders.
View Article and Find Full Text PDFBone Marrow Transplant
June 2022
Department of Hematology, Institut Curie, Site Saint-Cloud, France.
Anal Chem
April 2022
INSERM U1037 CNRS ERL5294 UPS, Cancer Research Center of Toulouse, 31000 Toulouse, France.
The clinical actionability of circulating tumor DNA requires sensitive detection methods with a short turnaround time. In the PADA-1 phase 3 trial (NCT03079011), metastatic breast cancer patients treated with an aromatase inhibitor and palbociclib were screened every 2 months for activating mutations in blood (). We report the feasibility of the droplet digital polymerase chain reaction (ddPCR) and cross-validation with next-generation sequencing (NGS).
View Article and Find Full Text PDFEur J Cancer
May 2022
Department of Surgical Oncology, Institut Curie, Paris & Saint-Cloud, France; Inserm U900, Cancer et Génome: Bioinformatique, Biostatistiques et épidémiologie, Institut Curie, Saint-Cloud, France.
Mod Pathol
August 2022
INSERM U955, Université Paris-Est, Créteil, France.
Nodal peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) with cytotoxic phenotype is overall rare, with most reports coming from Asia. Given its elusive pathobiology, we undertook a clinicopathological and molecular study of 54 Western patients diagnosed with PTCL, NOS expressing cytotoxic molecules, within a lymph node. More commonly males (M/F-2,6/1) with median age of 60 years were affected.
View Article and Find Full Text PDFBreast
June 2022
Department of Medical Oncology, Institut de Cancérologie Strasbourg - Europe (ICANS), 17 Rue Albert Calmette, BP 23025, 67033, Strasbourg, France.
Purpose: Trastuzumab-emtansine (T-DM1), as well as lapatinib plus capecitabine were proven effective in two Phase III studies, following first-line trastuzumab plus a taxane. The introduction of dual HER2 blockade by trastuzumab and pertuzumab as first-line has positioned T-DM1 into second-line, and lapatinib plus capecitabine beyond, without formal evaluation of these strategies.
Methods: ESME Data Platform (NCT03275311) included individual data from all patients aged ≥18 years, in whom first-line treatment for metastatic breast cancer (MBC) was initiated between January 1, 2008 and December 31, 2016 in one of the 18 French Comprehensive Cancer Centers.